论文部分内容阅读
目的分析探讨核苷类抗病毒药物脱氧核苷酸注射液的临床效果。方法选取我院2014年12月至2016年9月收治的慢性肝炎肝硬化患者为研究对象,随机分为对照组、观察组。对照组给予阿德福韦酯片剂,观察组给予阿德福韦酯脱氧核苷酸注射液。记录分析治疗前后患者的肝功能生化指标、HBV DNA变化情况、肝纤维化指标等。结果治疗后,两组患者的TBIL、ALT、AST含量均明显低于治疗前,与治疗前之间的差异具有统计学意义(P<0.05);观察组TBIL、ALT、AST含量均明显低于对照组(P<0.05);两组患者治疗后HBV DNA转阴率之间的差异无统计学意义(P>0.05);治疗后,两组患者的PCⅢ、Ⅳ-C、LN、HA含量均明显低于治疗前(P<0.05);观察组PCⅢ、Ⅳ-C、LN、HA含量均明显低于对照组(P<0.05)。结论阿德福韦酯脱氧核苷酸注射液能够有效改善慢性乙型肝炎患者的肝功能,缓解患者的肝纤维化。
Objective To analyze the clinical effect of nucleoside antiviral drug deoxynucleotide injection. Methods Selected patients with chronic hepatitis cirrhosis admitted from December 2014 to September 2016 in our hospital were randomly divided into control group and observation group. The control group was given adefovir dipivoxil tablets and the observation group was given adefovir dipivoxil injection. Records of patients before and after treatment of liver biochemical indicators, HBV DNA changes, liver fibrosis indicators. Results After treatment, the levels of TBIL, ALT and AST in both groups were significantly lower than those before treatment and before treatment (P <0.05). The levels of TBIL, ALT and AST in the two groups were significantly lower than those before treatment (P <0.05). There was no significant difference in the negative rate of HBV DNA between the two groups after treatment (P> 0.05). After treatment, the content of PCⅢ, Ⅳ-C, LN, (P <0.05). The contents of PCⅢ, Ⅳ-C, LN and HA in the observation group were significantly lower than those in the control group (P <0.05). Conclusion Adefovir dipivoxil injection can effectively improve the liver function in patients with chronic hepatitis B and relieve liver fibrosis in patients.